AI
CRSP icon

Axiom Investors’s CRISPR Therapeutics CRSP Stock Holding History

Axiom Investors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-35,688
Closed -$2.1M – 139
2018
Q2 		$2.1M Hold
35,688
– – 0.06% 125
2018
Q1 		$1.63M Buy
+35,688
New +$1.47M 0.04% 129

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Axiom Investors's CRSP Position: Q3 2018 in Review

Axiom Investors sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 35,688 shares — an estimated $2.1M sold.

Axiom Investors first reported a position in CRSP in Q1 2018 and held it in 2 quarters. The position peaked at $2.1M in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Axiom Investors reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Axiom Investors sold 35,688 CRISPR Therapeutics shares in Q3 2018, an estimated $2.1M.
  • Axiom Investors first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 2 quarters.
  • Axiom Investors's CRISPR Therapeutics position peaked at $2.1M in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Axiom Investors's 13F filing for Q3 2018, filed 13 Nov 2018.